Opdivo (nivolumab) significantly prolongs the time patients with resected esophageal or gastroesophageal junction (GEJ) cancer live without signs of disease after receiving chemoradiation therapy followed by cancer removal surgery, interim data from a Phase 3 trial show. Consistent with data from previous studies, Opdivo demonstrated a favorable safety profile in this setting. This is the … Continue reading Post-surgery Opdivo Shows Benefits for Esophageal, GEJ Cancer Patients in Ongoing Trial